Agenda: Workshop on Neuroscience Biomarkers and Biosignatures: Converging Technologies, Emerging Partnerships
Workshop Objectives
Discuss the most promising, and practical, arenas in neuroscience in which novel biomarkers will have greatest near-term impact on the rate at which new treatments are brought forward for psychiatric and neurological disorders. Discuss the necessary parameters for such a high impact biomarker. Discuss potential partnerships needed to advance the development of biomarkers and biosignatures.
8:30 a.m. Welcome and Introductions
Alan Leshner, Forum Chair
Chief Executive Officer, AAAS
Executive Publisher, Science
Session I: Biomarker and Biosignature Principles
8:40 a.m. Workshop Objectives: What Parameters should be considered when developing a
high-impact biomarker?
Dennis Choi, Workshop Chair
Professor of Pharmacology & Experimental Therapeutics
Boston University
8:50 a.m. Introduction to the fNIH Biomarkers Consortium
Tom Insel
Director
National Institute on Mental Health
9:10 a.m. Lessons Learned from Alzheimer’s Disease and the NIA Alzheimer’s Disease
Neuroimaging Initiative
William Potter
Vice President
Merck Research Laboratories
Clinical Neuroscience
Session II: Potential Tools for Biomarker and Biosignature Development
Session objective: Discuss which tools and parameters should be considered when developing a high impact biomarker for the neurological or psychiatric disorders.
Alan Breier, Session Chair
Vice President for Medical and Chief Medical Officer
Eli Lilly and Company
9:30 a.m. What Impact will the Genomics Field have on the Immediate on the Near-term
Development of Biomarkers for Nervous System Diseases?
Allen Roses
Senior Vice President
GlaxoSmithKline
9:50 a.m. What Impact will Proteomics, Including CSF Analysis, have on the Near-term
Development of Biomarkers for Nervous System Diseases?
Howard Schulman
Vice President
PPD Biomarker Discovery Sciences
10:10 a.m. BREAK
10:30 a.m. What Imaging Tools May be Utilized for the Development of Biomarkers
for Nervous System Diseases?
Bruce Rosen
Associate Director
Athinoula A. Martinos Center for Biomedical Imaging
Massachusetts General Hospital
10:50 a.m. Panel Discussion with Meeting Attendees
Alan Breier, Session Chair
11:30 a.m. LUNCH
Session III: Psychiatric Diseases and Drug Addiction Disorders
Session Objective: Identify specific areas of psychiatric medicine where the development of a novel biomarker could have a high impact.
Tom Insel,
Session Chair
Director
National Institute on Mental Health
12:30 p.m. Which Psychiatric Disorders are Primed for Key Advances in Biomarker
Development?
Steven Hyman
Provost
Harvard University
12:45 p.m. Current and Near-term Impact of Biomarkers for Depression
Husseini Manji
Director, Mood and Anxiety Disorders Program
National Institute of Mental Health
1:05 p.m. Current and Near-term Impact of Biomarkers for Schizophrenia
David Lewis
Professor of Psychiatry
University of Pittsburgh Medical Center
1:25 p.m. Current and Near-term Impact of Biomarkers for Disorders of Addiction
Nora Volkow
Director
National Institute on Drug Abuse
1:45 p.m. Panel Discussion with Meeting Attendees
Tom Insel, Session Chair
2:15 p.m. BREAK
Session IV: neurological and Eye diseases
Session objective: Discuss specific areas of neurological medicine where the development of a novel biomarker could have a high impact.
Story Landis,
Session Chair
Director
National Institute for Neurological Disorders and Stroke
2:30 p.m. Which Neurological Diseases are Primed for Key Advances in Biomarker
Development?
Ira Shoulson
Professor of Neurology
University of Rochester
2:45 p.m. Current and Near-term Impact of Biomarkers for Multiple Sclerosis
Gavin Giovannoni
Professor of Neurology
Institute of Cell and Molecular Science
Queen Mary University London
3:05 p.m. Current and Near-term Impact of Biomarkers for Stroke
Steven Warach
Chief
Section on Stroke Diagnostics and Therapeutics
National Institute for Neurological Disorders and Stroke
3:25 p.m. Current and Near-term Impact of Biomarkers for SMA
Meg Winberg
Research Director
Spinal Muscular Atrophy Foundation
3:45 p.m. Current and Near-term Impact of Biomarkers for Retinal Degeneration
Paul Sieving
Director
National Eye Institute
4:05 p.m. Panel Discussion with Meeting Attendees
Story Landis, Session Chair
Session V: Regulatory Considerations, Next Steps, and General Discussion
4:35 p.m. What Regulatory Considerations are Important to Developing a Qualified
Biomarker?
Janet Woodcock
Deputy Commissioner and Chief Medical Officer
Food and Drug Administration
4:55 p.m. General Discussion
- Which biomarkers have the greatest potential for near-term impact on the development of treatments or key diagnostics for nervous system diseases?
- What partnerships are needed to move forward?
Dennis Choi, Workshop Chair
Professor of Pharmacology & Experimental Therapeutics
Boston University
5:30 p.m. ADJOURN
Back to Meeting